Diasorin SpA (MIL:DIA) Moat Score: 6/10 (As of Jul. 01, 2026)


MIL:DIA Diasorin SpA MIL:DIA
71 GF Score
Price €67.76
GF Value €90.16
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Diasorin SpA Moat Score?

Diasorin SpA MIL:DIA -3.14% 71 Moat Score is 6 as of Jul. 01, 2026. GuruFocus rates MIL:DIA with a GF Score™ of 71/100 and a GF Value™ of €90.16 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 93.98% on this metric.

Diasorin SpA has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Diasorin SpA has Narrow Moat: Diasorin SpA has a strong narrow moat due to its proprietary technology and valuable patents in the diagnostics industry. It benefits from regulatory barriers and has a strong brand in its niche. However, its market share is not dominant enough for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Diasorin SpA might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Diasorin SpA  (MIL:DIA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Diasorin SpA Moat Score Related Terms

MIL:DIA vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Diasorin SpA's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diasorin SpA Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Moat Score distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's Moat Score falls into.


MIL:DIA
71GF Score
Diasorin SpA MIL:DIA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Diasorin SpA (MIL:DIA) has a Moat Score of 6 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Diasorin SpA ranks #13 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 6%.
Is Diasorin SpA's Moat Score too high?
Diasorin SpA's current Moat Score is 6. Based on the distribution chart, Diasorin SpA ranks #13 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diasorin SpA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #13 out of 216 companies for Moat Score. This places Diasorin SpA in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Diasorin SpA's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.16, compared to a current price of €67.76 — trading 24.8% below its estimated fair value. The current Moat Score is 6. Diasorin SpA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current Moat Score is 6 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (MIL:DIA) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €67.76 is trading 24.8% below its estimated GF Value™ of €90.16. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for MIL:DIA:

  • Moat Score: 6
  • GF Value™: €90.16 vs. price of €67.76 (24.8% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
71GF Score

Get the complete analysis for MIL:DIA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.76
Price
€90.16
GF Value